



Distribuito in ITALIA da  
**Li StarFish S.r.l.**  
Via Cavour, 35  
20063 Cernusco S/N (MI)  
telefono 02-92150794  
info@listarfish.it  
www.listarfish.it

**Manual**

# **IDK<sup>®</sup> Hemoglobin ELISA**

*For the in vitro determination of hemoglobin in stool*


Valid from 2020-02-01

**REF** K 7836D

$\Sigma$  96

**REF** K 7836D.20

$\Sigma$  20x 96



**IVD**



**Immundiagnostik AG**, Stubenwald-Allee 8a, 64625 Bensheim, Germany

Tel.: +49 6251 70190-0

Fax: + 49 6251 70190-363

e.mail: info@immundiagnostik.com

www.immundiagnostik.com

# Table of Contents

<b>1. INTENDED USE</b>	<b>19</b>
<b>2. INTRODUCTION</b>	<b>19</b>
<b>3. MATERIAL SUPPLIED</b>	<b>19</b>
<b>4. MATERIAL REQUIRED BUT NOT SUPPLIED</b>	<b>20</b>
<b>5. PREPARATION AND STORAGE OF REAGENTS</b>	<b>20</b>
<b>6. STORAGE AND PREPARATION OF SAMPLES</b>	<b>21</b>
<i>Sample stability and storage</i>	21
<i>Extraction of the stool samples</i>	21
<b>7. ASSAY PROCEDURE</b>	<b>23</b>
<i>Principle of the test</i>	23
<i>Test procedure</i>	23
<b>8. RESULTS</b>	<b>24</b>
<b>9. LIMITATIONS</b>	<b>25</b>
<b>10. QUALITY CONTROL</b>	<b>25</b>
<i>Reference range</i>	25
<b>11. PERFORMANCE CHARACTERISTICS</b>	<b>26</b>
<i>Accuracy – Precision</i>	26
<i>Analytical specificity</i>	26
<i>Analytical sensitivity</i>	27
<i>Accuracy – Trueness</i>	27
<i>Clinical sensitivity and specificity</i>	28
<i>Linearity</i>	28
<b>12. PRECAUTIONS</b>	<b>29</b>
<b>13. TECHNICAL HINTS</b>	<b>29</b>
<b>14. GENERAL NOTES ON THE TEST AND TEST PROCEDURE</b>	<b>29</b>
<b>15. REFERENCES</b>	<b>30</b>
<i>General literature</i>	30
<i>Literature using the IDK® hemoglobin ELISA</i>	30

## 1. INTENDED USE

This immunoassay is intended for the quantitative determination of human haemoglobin in stool, e.g. for colorectal cancer screening. For *in-vitro* diagnostic use only.

## 2. INTRODUCTION

In colon cancer prevention, the detection of haemoglobin in stool can be used as marker for gastrointestinal bleedings. Tumours and polyps are a possible source of blood in stool. After the detection of haemoglobin, a colonoscopy has to be performed to clarify if the blood comes indeed from a tumour or a tumour precursor. In combination with colonoscopy, the hemoglobin stool assay is proven to be able to reduce the risk of mortality due to colon cancer.

The advantage of the *IDK*® hemoglobin ELISA over guaiac-based tests is its sensitive and specific detection of exclusively human hemoglobin. It is not necessary to follow a special diet before drawing a stool sample for the *IDK*® hemoglobin ELISA, as neither raw meat, radish, nor food containing vitamin C have an influence on the test result.

### Indications

- Detection of occult blood in stool
- Crohn's disease; ulcerative colitis
- Suspicion of colon carcinoma
- Polyps in the colon

## 3. MATERIAL SUPPLIED

Label	Kit components	Quantity for cat. no.	
		K 7836D	K 7836D.20
PLATE	Microtiter plate, pre-coated	12 x 8 wells	20 x 12 x 8 wells
WASHBUF	Wash buffer concentrate, 10x	2 x 100 ml	40 x 100 ml
IDK Extract®	Extraction buffer concentrate <i>IDK Extract</i> ®, 2.5 x	1 x 100 ml	–
SAMPLEBUF	Sample dilution buffer, ready-to-use	2 x 15 ml	3 x 100 ml
CONJ	Conjugate, (mouse anti-human Hb, peroxidase-labelled), ready-to-use	1 x 15 ml	20 x 15 ml
CAL	Calibrator, lyophilised	2 x 1 vial	25 x 1 vial

Label	Kit components	Quantity for cat. no.	
		K 7836D	K 7836D.20
HC	High control, lyophilised (see specification for range)	2 x 1 vial	25 x 1 vial
LC	Low control, lyophilised (see specification for range)	2 x 1 vial	25 x 1 vial
SUB	Substrate (tetramethylbenzidine), ready-to-use	1 x 15 ml	20 x 15 ml
STOP	Stop solution, ready-to-use	1 x 15 ml	20 x 15 ml

For reorders of single components, use the catalogue number followed by the label as product number.

#### 4. MATERIAL REQUIRED BUT NOT SUPPLIED

- Ultrapure water\*
- Stool sample application system such as Cat. No.: K 6998SAS
- Calibrated precision pipettors and 10–1000 µl single-use tips
- Foil to cover the microtiter plate
- Multi-channel pipets or repeater pipets
- Centrifuge, 3000 g
- Vortex
- Standard single-use laboratory glass or plastic vials, cups, etc.
- Microtiter plate reader (required filters see chapter 7)

\* Immundiagnostik AG recommends the use of ultrapure water (water type 1; ISO 3696), which is free of undissolved and colloidal ions and organic molecules (free of particles > 0.2 µm) with an electrical conductivity of 0.055 µS/cm at 25 °C (≥ 18.2 MΩ cm).

#### 5. PREPARATION AND STORAGE OF REAGENTS

- To run the assay more than once, ensure that reagents are stored at the conditions stated on the label. **Prepare only the appropriate amount necessary for each run.** The kit can be used up to 4 times within the expiry date stated on the label.
- Reagents with a volume less than **100 µl** should be centrifuged before use to avoid loss of volume.
- **Preparation of the wash buffer:** The **wash buffer concentrate (WASHBUF)** has to be diluted with ultrapure water **1:10** before use (100 ml WASHBUF + 900 ml ultrapure water), mix well. Crystals could occur due to high salt con-

centration in the concentrate. Before dilution, the crystals have to be redissolved at room temperature or in a water bath at 37°C. The **WASHBUF** is stable at **2–8°C** until the expiry date stated on the label. **Wash buffer** (1:10 diluted WASHBUF) can be stored in a closed flask **for 1 month at 2–8°C**.

- **Preparation of the extraction buffer:** The **extraction buffer concentrate IDK Extract®** has to be diluted with ultrapure water **1:2.5** before use (100 ml *IDK Extract®* + 150 ml ultrapure water), mix well. Crystals could occur due to high salt concentration in the concentrate. Before dilution, the crystals have to be redissolved at 37°C in a water bath. The *IDK Extract®* is stable at **2–8°C** until the expiry date stated on the label. Extraction buffer (1:2.5 diluted *IDK Extract®*) can be stored in a closed flask **for 4 months at 2–8°C**.
- The **lyophilised calibrator (CAL)**, **high control (HC)** and **low control (LC)** are stable at **2–8°C** until the expiry date stated on the label. Before use, the CAL, HC and LC have to be reconstituted with **500 µl of ultrapure water**. Allow the vial content to dissolve for 10 minutes and mix thoroughly to ensure complete reconstitution. **Calibrator and controls** (reconstituted CAL, HC and LC) **can be stored at 2–8°C for 4 weeks**.
- **Please dispense 50 µl of sample dilution buffer (SAMPLEBUF) as BLANK into the respective well.**
- All other test reagents are ready-to-use. Test reagents are stable until the expiry date (see label) when stored at **2–8°C**.

## 6. STORAGE AND PREPARATION OF SAMPLES

### *Sample stability and storage*

Due to the degradation of hemoglobin at room temperature, which can amount to 50% per day, **raw stool** samples should be shipped frozen. If shipment either at -20°C or cooled is not possible, the samples can be mailed overnight, but this will reduce the sensitivity. Raw stool can be stored at -20°C for 1 month.

**Stool extract** is stable at room temperature\* (15-30°C), 2–8°C as well as at -20°C for 7 days. Avoid more than three freeze-thaw cycles.

\* under the requirements of the G-BA-Beschluss of 21.04.2016

### *Extraction of the stool samples*

We recommend the following sample preparation:

## Stool Sample Application System (SAS) (Cat. No.: K 6998SAS)

### **Stool sample tube – Instructions for use**

Please note that the dilution factor of the final stool suspension depends on the amount of stool sample used and the volume of the buffer.

#### **SAS with 1.5 ml extraction buffer:**

Applied amount of stool:	15 mg
Buffer Volume:	1.5 ml
Dilution Factor:	1:100

Please follow the instructions for the preparation of stool samples using the SAS as follows:

- a) The raw stool sample has to be thawed. For particularly heterogeneous samples we recommend a mechanical homogenisation using an applicator, inoculation loop or similar device.
- b) **Fill the empty sample tube with 1.5 ml extraction buffer** (1:2.5 diluted *IDK Extract*<sup>®</sup>) before using it with the sample. Important: Allow the extraction buffer to reach room temperature.
- c) Unscrew the tube (yellow part of cap) to open. Insert the yellow dipstick into the sample. The lower part of the dipstick has notches which need to be covered completely with stool after inserting it into the sample. Place dipstick back into the tube. When putting the stick back into the tube, excess material will be stripped off, leaving 15 mg of sample to be diluted. Screw tightly to close the tube.
- d) Vortex the tube well until no stool sample remains in the notches. **Important:** Please make sure that you have a maximally homogenous suspension after shaking. Especially with more solid samples, soaking the sample in the tube with buffer for ~ 10 minutes improves the result.
- e) Allow sample to stand for ~10 minutes until sediment has settled. Floating material like shells of grains can be neglected.
- f) Carefully unscrew the complete cap of the tube including the blue ring plus the dipstick. Discard cap and dipstick. Make sure that the sediment will not be dispersed again.

The sample suspension is now ready for use.

The sample can also be used in a pipetting automat. Place the sample in the sample rack according to instrument instructions.

## 7. ASSAY PROCEDURE

### *Principle of the test*

This ELISA is designed for the quantitative determination of hemoglobin in stool. The hemoglobin in the sample is bound to anti-hemoglobin antibodies (in excess), which are immobilised on the surface of the microtiter wells. To remove all unbound substances, a washing step is carried out. In a second incubation step an anti-hemoglobin peroxidase labeled antibody is added. After another washing step, to remove all unbound substances, the solid phase is incubated with the substrate, tetramethylbenzidine (TMB). An acidic solution is then added to stop the reaction. The colour converts from blue to yellow. The intensity of the yellow colour is directly proportional to the concentration of hemoglobin in the sample. Hemoglobin, present in the patient samples, is quantified by referring the optical density of patient's samples to a lot-dependant master calibration curve. This is done by using a reference/calibrator that is run with each test.

### *Test procedure*

Bring all **reagents to room temperature** (15–30°C) and mix well.

Bring **frozen sample suspensions to room temperature** (15–30°C) and then vortex. Allow the sample to stand for ~10 minutes until sediment has settled before using the supernatant in the test.

Mark the positions of calibrator/controls/blank/samples on a protocol sheet.

Take as many microtiter strips as needed from the kit. Store unused strips together with the desiccant bag in the closed aluminium packaging at 2–8°C. Strips are stable until expiry date stated on the label.

For automated ELISA processors, the given protocol may need to be adjusted according to the specific features of the respective automated platform. For further details please contact your supplier or Immundiagnostik AG.

We recommend to carry out the tests in duplicate.

1.	Wash the pre-coated microtiter plate <b>5 times with 250 µl wash buffer before use</b> . After the final washing step, remove residual wash buffer by firmly tapping the plate on absorbent paper.
2.	Add <b>50 µl sample dilution buffer</b> (SAMPLEBUF) into each well.
3.	Add <b>50 µl high control/low control/calibrator/blank/supernatant</b> into respective well.
4.	<b>Incubate for 1 hour</b> at room temperature (15–30°C).

5.	Discard the contents of each well and wash <b>5 times</b> with <b>250 µl wash buffer</b> . After the final washing step, remove residual wash buffer by firmly tapping the plate on absorbent paper.
6.	Add <b>100 µl conjugate</b> (CONJ) into each well.
7.	<b>Incubate for 1 hour</b> at room temperature (15–30 °C).
8.	Discard the contents of each well and wash <b>5 times</b> with <b>250 µl wash buffer</b> . After the final washing step, remove residual wash buffer by firmly tapping the plate on absorbent paper.
9.	Add <b>100 µl substrate</b> (SUB) into each well.
10.	<b>Incubate for 10–20 minutes</b> at room temperature (15–30 °C) in the <b>dark</b> .*
11.	Add <b>100 µl stop solution</b> (STOP) into each well and mix well.
12.	Determine <b>absorption immediately</b> with an ELISA reader at <b>450 nm</b> against 620 nm (or 690 nm) as a reference. If no reference wavelength is available, read only at 450 nm. If the extinction of the highest standard exceeds the range of the photometer, absorption must be measured immediately at <b>405 nm</b> against 620 nm as a reference.

\* The intensity of the colour change is temperature sensitive. We recommend observing the colour change and stopping the reaction upon good differentiation.

## 8. RESULTS

For result evaluation, please use a four parametric logit-log model based on the standard curve of the respective kit lot and the Calibrator value (CAL). All essential information on the standard curve is provided on the QC data sheet of the respective product lot.

The calibration curve can be expressed either by the concentration of each standard with its corresponding optical density or by the four parameters A, B, C and D. In both cases the optical density of the calibrator (CAL) is essential.

Depending on your evaluation software program, either the one or the other kind of data described above should be entered.

**Caution:** Please make sure that all parameters and values are transferred accurately into your software as minor deviations can cause severe errors during evaluation.



The plausibility of the duplicate values should be examined before the automatic evaluation of the results. If this option is not available with the programme used, the duplicate values should be evaluated manually.

### Stool

Since the sample dilution is already considered in the calibration curve, the dilution factor is **1**.

In case **another dilution factor** has been used, multiply the obtained result with the dilution factor used.

## 9. LIMITATIONS

Samples with concentrations above the measurement range (see definition below) can be further diluted and re-assayed. Please consider this higher dilution when calculating the results.

Samples with concentrations lower than the measurement range cannot be clearly quantified.

The upper limit of the measurement range can be calculated as:

*highest concentration of the standard curve × sample dilution factor to be used*

The lower limit of the measurement range can be calculated as:

*LoB × sample dilution factor to be used*

LoB see chapter "Performance Characteristics".

## 10. QUALITY CONTROL

Immundiagnostik AG recommends the use of external controls for internal quality control, if possible.

Control samples should be analysed with each run. Results, generated from the analysis of control samples, should be evaluated for acceptability using appropriate statistical methods. The results for the patient samples may not be valid if within the same assay one or more values of the quality control sample are outside the acceptable limits.

### *Reference range*

We recommend each laboratory to establish its own reference range.

Based on a study from Gies *et al.* of 516 stool samples, the cut-off value was estimated to be 10 µg/g for colorectal cancer screening.

## 11. PERFORMANCE CHARACTERISTICS

### *Accuracy – Precision*

#### **Repeatability (Intra-Assay); n = 42**

The repeatability was assessed with 2 stool samples under **constant** parameters (same operator, instrument, day and kit lot).

Sample	Mean value [µg/g]	CV [%]
1	7.00	2.6
2	3.99	4.8

#### **Reproducibility (Inter-Assay); n = 68**

The reproducibility was assessed with 2 stool samples under **varying** parameters (different operators, instruments, days and kit lots).

Sample	Mean value [µg/g]	CV [%]
1	0.87	8.6
2	3.51	4.8

### *Analytical specificity*

The specificity of the antibody was tested by measuring the cross-reactivity against 6 compounds with structural similarity to hemoglobin. There was no cross-reactivity observed.

Substance tested	Concentration added	Concentration obtained [µg/g]	Conclusion
Pankreatic amylase	2800 mU/l	0.026	< LoB
Myeloperoxidase	315.5 ng/ml	0.038	< LoB
Lysozyme	30 ng/ml	0.021	< LoB
Chymotrypsin	1000 ng/ml	0.028	< LoB
slgA	600 ng/ml	0.023	< LoB
Albumin	6250 ng/ml	0.001	< LoB

### Analytical sensitivity

The following values have been estimated based on the concentrations of the standard without considering possibly used sample dilution factors

Limit of blank, LoB	0.086 µg/g
Limit of detection, LoD	0.152 µg/g
Limit of quantitation, LoQ	0.177 µg/g

The evaluation was performed according to the CLSI guideline EP17-A2. The specified accuracy goal for the LoQ was 20 % CV.

### Accuracy – Trueness

The trueness states the closeness of the agreement between the result of a measurement and the true value of the measurand. Therefore, hemoglobin-spikes with known concentrations were added to 3 different stool samples.

Sample	Spike [µg/g]	Obtained [µg/g]	Expected [µg/g]	Recovery [%]
A	unspiked	19.23	–	–
	1.53	20.96	20.76	100.96
	3.06	22.74	22.29	102.02
	7.65	27.67	26.88	102.94
	15.30	34.35	34.53	99.47
B	unspiked	11.03	–	–
	1.53	12.18	12.56	96.93
	3.06	13.36	14.09	94.76
	7.65	17.77	18.69	95.11
	15.30	24.64	26.34	93.57
C	unspiked	1.42	–	–
	1.53	2.76	2.95	93.55
	3.06	4.47	4.48	99.83
	7.65	9.54	9.07	105.16
	15.30	17.44	16.72	104.27

### *Clinical sensitivity and specificity*

Based on a study of Gies et al. [6], the *IDK*<sup>®</sup> hemoglobin ELISA results in a clinical specificity of 95.0% and a clinical sensitivity of 27.3% for advanced neoplasms (colorectal cancer [CRC] and large adenoma) with a cut-off of 10 µg hemoglobin/g stool. The expected positivity rate for corresponding samples in an organised colorectal cancer screening is 8.1% as calculated from a collection of representative stool samples.

In a study of Hoepffner et al. [5], a cut-off value of 2.0 µg hemoglobin/g stool for the *IDK*<sup>®</sup> Hemoglobin ELISA resulted in a highest clinical sensitivity of 63.8% for CRC and large adenoma. The respective clinical specificity was 96.3%.

### *Linearity*

The linearity states the ability of a method to provide results proportional to the concentration of analyte in the test sample within a given range. This was assessed according to CLSI guideline EP6-A by serial dilution of 4 different stool samples. In the table below, the dilution of 2 exemplary samples is shown.

For hemoglobin in stool, the method has been demonstrated to be linear from 0.44 to 23.75 µg/g, showing a non-linear behaviour of less than ± 20% in this interval.

Sample	Dilution	Expected [µg/g]	Obtained [µg/g]	Recovery [%]
A	undiluted	23.75	23.75	–
	1:2	11.87	13.83	116.49
	1:4	5.94	6.74	113.61
	1:8	2.97	3.52	118.49
	1:16	1.48	1.61	108.42
	1:32	0.74	0.68	91.37
	1:64	0.37	0.30	80.32
B	undiluted	16.56	16.56	–
	1:2	8.28	7.48	90.31
	1:4	4.14	3.95	95.31
	1:8	2.07	1.80	87.05
	1:16	1.04	0.91	87.44
	1:32	0.52	0.44	84.44

## 12. PRECAUTIONS

- All reagents in the kit package are for *in vitro* diagnostic use only.
- Human materials used in kit components were tested and found to be negative for HIV, Hepatitis B and Hepatitis C. However, for safety reasons, all kit components should be treated as potentially infectious.
- Kit reagents contain sodium azide or Proclin as bactericides. Sodium azide and Proclin are toxic. Substrates for the enzymatic colour reactions are toxic and carcinogenic. Avoid contact with skin or mucous membranes.
- The stop solution consists of diluted sulphuric acid, a strong acid. Although diluted, it still must be handled with care. It can cause burns and should be handled with gloves, eye protection, and appropriate protective clothing. Any spill should be wiped up immediately with copious quantities of water. Do not breath vapour and avoid inhalation.

## 13. TECHNICAL HINTS

- Do not interchange different lot numbers of any kit component within the same assay. Furthermore we recommend not assembling wells of different microtiter plates for analysis, even if they are of the same batch.
- Control samples should be analysed with each run.
- Reagents should not be used beyond the expiration date stated on kit label.
- Substrate solution should remain colourless until use.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- Avoid foaming when mixing reagents.
- Do not mix plugs and caps from different reagents.
- The assay should always be performed according to the enclosed manual.

## 14. GENERAL NOTES ON THE TEST AND TEST PROCEDURE

- This assay was produced and distributed according to the IVD guidelines of 98/79/EC.
- The guidelines for medical laboratories should be followed.
- *IDK*<sup>®</sup> and *IDK Extract*<sup>®</sup> are trademarks of Immundiagnostik AG.

- Incubation time, incubation temperature and pipetting volumes of the components are defined by the producer. Any variation of the test procedure, which is not coordinated with the producer, may influence the results of the test. Immundiagnostik AG can therefore not be held responsible for any damage resulting from incorrect use.
- Warranty claims and complaints regarding deficiencies must be logged within 14 days after receipt of the product. The product should be send to Immundiagnostik AG along with a written complaint.

## 15. REFERENCES












### *General literature*

1. Lüthgens, K. et al., 1998. Hemoglobin-Haptoglobin-Complex: A Highly Sensitive Assay for the Detection of Fecal Occult Blood. *Clinical laboratory*, **44**, pp.543–551.
2. Thomas, L., 1998. Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik **5th ed.**, Frankfurt/Main: *TH-Books Verlagsgesellschaft*.
3. John, M. et al., 1994. Nachweis von Albumin im Stuhl zur Erkennung okkultur Blutungen : Vergleich zweier immunologischer Tests . Radiale Immundiffusion vs BM-Test Colon Albumin. *Klinisches Labor*, **40**, pp.77–81.

### *Literature using the IDK® hemoglobin ELISA*

4. Trojan, J. et al., 2002. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. *Zeitschrift für Gastroenterologie / German Journal of Gastroenterology*, **40**, pp.921–924.
5. Hoepffner, N. et al., 2006. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. *Alimentary pharmacology & therapeutics*, **23**(1), pp.145–54.
6. Gies A, Cuk K, Schrotz-King P, Brenner H. Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening. *Gastroenterology*. 2018;154(1):93-104. doi: 10.1053/j.gastro.2017.09.018. Epub 2017 Sep 25.

**Used symbols:**

	Temperature limitation		Catalogue Number
	In Vitro Diagnostic Medical Device		To be used with
	Manufacturer		Contains sufficient for <n> tests
	Lot number		Use by
	Attention		Consult instructions for use
	Consult specification data sheet		